1 2	A Clinical Consensus Treatment Algorithm for Patients with High-tone Pelvic Floor Dysfunction: a Multidisciplinary Delphi Study
3	
4 5	Michele Torosis MD ¹ , Erin Carey MD ² , Kristin Christensen DPT ³ , Melissa R. Kaufman MD PhD ⁴ , Kimberly Kenton MD ⁵ , Rhonda Kotarinos DPT ⁶ , H. Henry Lai MD ⁷ , Una Lee MD ⁸ , Jerry L. Lowder
6	MD, MSc ⁹ , Melanie Meister MD ¹⁰ , Theresa Spitznagle DPT ¹¹ , Kelly Wright MD ³ , A. Lenore
7	Ackerman MD PhD ¹²
8	
9	¹ Department of Obstetrics and Gynecology, UCLA, Los Angeles, CA, ² Department of Obstetrics and Gynecology,
10	UNC, Chapel Hill, NC, ³ Cedars-Sinai Medical Center, Los Angeles, CA ⁴ Department of Urology, Vanderbilt, Nashville,
11 12	TN, ⁵ Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, ⁶ Kotarinos Physical Therapy, Lake
13	<i>Zurich, IL,</i> ⁷ <i>Division of Urologic Surgery, Departments of Surgery and Anesthesiology, Washington University, Saint Louis, MO,</i> ⁸ <i>Department of Urology, Virginia Mason, Seattle, WA,</i> ⁹ <i>Department of Obstetrics and Gynecology,</i>
14	Washington University, Saint Louis, MO, ¹⁰ Obstetrics and Gynecology, University of Kansas, Kansas City, KS,
15	¹¹ Washington University, Saint Louis, MO, ¹² Department of Urology, UCLA, Los Angeles, CA
16	
17	Short Title: A Consensus Treatment Algorithm for High-tone Pelvic Floor Dysfunction
18	
19	Conflict of Interest: A.L. Ackerman receives grant funding from Medtronic, Inc. and
20	MicrogenDx. A.L. Ackerman is an advisor for Abbvie and Watershed Medical.
21	
22	Source of Funding: No funding was involved in this paper
23	
24	Corresponding Author:
25	A. Lenore Ackerman
26	10833 Le Conte Ave, Box 951738
27	Los Angeles, CA 90095-1738
28	Phone: 833-825-2974
29	AAckerman@mednet.ucla.edu
30	Word Count: 2795
31	
32	Acknowledgments: The study team members acknowledge with gratitude the panelists who
33	completed the Delphi surveys.
34	
35	Keywords (alphabetized, 10 words): chronic pelvic pain, high-tone pelvic floor dysfunction,
36	
37	
34 35 36	

39 AUTHOR SUMMARY

40 Why was this study done?

- 41 High tone pelvic floor dysfunction is a highly prevalent neuromuscular disorders causing a range
- 42 of lower urinary tract and defecatory symptoms, sexual dysfunction, and pelvic pain.
- 43 Currently, there is no consensus or accepted clinical guidance to direct the management of
- 44 these patients.

45 What did the researchers do and find?

- 46 Experts in urology, urogynecology, minimally invasive gynecology, and pelvic floor physical
- 47 therapy generated a set of consensus practice statements to help guide the management of
- 48 HTPFD using a rigorous Delphi process.
- 49 Four tiers of treatment, with pelvic floor physical therapy as the first line treatment, followed
- 50 by vaginal muscle relaxants, tender point injections, and/or cognitive behavioral therapy as
- 51 second line, pelvic floor trigger point injection as third-line, and sacral neuromodulation as
- 52 fourth line, were recommended for HTPFD management.
- 53 Exceptions to sequential progression through this algorithm may be needed for patients with
- 54 limited regional or financial access to the recommended treatments.

55 What do these findings mean?

- 56 A clinical care pathway for high-tone pelvic floor dysfunction will enable more effective care of
- 57 patients and empower future studies to measure the effectiveness of each treatment option in
- 58 a more systematic fashion.

4

60 ABSTRACT

61 BACKGROUND: High-tone pelvic floor dysfunction (HTPFD) is a neuromuscular disorder of the pelvic floor characterized by non-relaxing pelvic floor muscles, resulting in lower urinary tract 62 63 and defecatory symptoms, sexual dysfunction, and pelvic pain. Despite affecting 80% of women 64 with chronic pelvic pain, there are no uniformly accepted guidelines to direct the management 65 of these patients. We sought to develop evidence- and consensus-based clinical practice 66 guidelines for management of HTPFD. 67 METHODS AND FINDINGS: A Delphi method of consensus development was used, comprising 68 three survey rounds administered anonymously via web-based platform (Qualtrics® XM) to 69 national experts in the field of HTPFD recruited through targeted invitation between September 70 and December 2021. Twelve experts participated with backgrounds in urology, urogynecology, 71 minimally invasive gynecology, and pelvic floor physical therapy (PFPT) participated. Panelists 72 were asked to rate their agreement with rated evidence-based statements regarding HTPFD 73 treatment. Statements reaching consensus were used to generate a consensus treatment 74 algorithm. A total of 31 statements were reviewed by group members at the first Delphi round 75 with 10 statements reaching consensus. 28 statements were reposed in the second round with 76 17 reaching consensus. The putative algorithm met clinical consensus in the third round. There 77 was universal agreement for PFPT as first-line treatment for HTPFD. If satisfactory symptom 78 improvement is reached with PFPT, the patient can be discharged with a home exercise program. If no improvement after PFPT, second line options include trigger or tender point 79 80 injections, vaginal muscle relaxants, and cognitive behavioral therapy, all of which can also be 81 used in conjunction with PFPT. Onabotulinumtoxin A injections should be used as third line with

82	symptom assessment after	2-4two to four weeks.	There was universal	agreement that sacral
----	--------------------------	-----------------------	---------------------	-----------------------

- 83 neuromodulation is fourth line intervention. The largest identified barrier to care for these
- 84 patients is access to PFPT. For patients who cannot access PFPT, experts recommend at-home,
- 85 guided pelvic floor relaxation, self-massage with vaginal wands, and virtual PFPT visits.
- 86 **CONCLUSIONS**: A stepwise approach to the treatment of HTPFD is recommended, with patients
- 87 often necessitating multiple lines of treatment either sequentially or in conjunction. However,
- 88 PFPT should be offered first line.

6

89 INTRODUCTION

90	Chronic pelvic pain (CPP) is estimated to affect one quarter of women and cost the US
91	healthcare system more than \$5.8 billion annually. (1) (2) High-tone pelvic floor disorder
92	(HTPFD), a chronic pelvic floor disorder characterized by tight, weakened, and/or painful pelvic
93	floor muscles, is present in 60 to 90% of women with CPP. (1) (3) (4) Tension within the muscle
94	interferes with its dynamic physiologic action, preventing appropriate coordination,
95	contraction, and relaxation. This may be associated with a wide range of genitourinary
96	complaints, including discomfort, lower urinary tract symptoms (LUTS), defecatory dysfunction,
97	and dyspareunia. HTPFD can be the sole cause for pain and genitourinary complaints or can co-
98	exist with other pelvic pain disorders, such as vulvodynia or endometriosis; however, it
99	frequently goes both unrecognized and untreated, contributing to the poor outcomes often
100	seen in these conditions.
100 101	seen in these conditions.
	seen in these conditions. Recognition and diagnosis of HTPFD is complicated by its wide spectrum of clinical
101	
101 102	Recognition and diagnosis of HTPFD is complicated by its wide spectrum of clinical
101 102 103	Recognition and diagnosis of HTPFD is complicated by its wide spectrum of clinical presentations and symptomatic overlap with other gynecologic, urologic and colorectal
101 102 103 104	Recognition and diagnosis of HTPFD is complicated by its wide spectrum of clinical presentations and symptomatic overlap with other gynecologic, urologic and colorectal syndromes. While chronic pain is a common presentation, many patients with HTPFD may seek
101 102 103 104 105	Recognition and diagnosis of HTPFD is complicated by its wide spectrum of clinical presentations and symptomatic overlap with other gynecologic, urologic and colorectal syndromes. While chronic pain is a common presentation, many patients with HTPFD may seek medical care for LUTS or defecatory dysfunction as their primary complaint. A growing body of
101 102 103 104 105 106	Recognition and diagnosis of HTPFD is complicated by its wide spectrum of clinical presentations and symptomatic overlap with other gynecologic, urologic and colorectal syndromes. While chronic pain is a common presentation, many patients with HTPFD may seek medical care for LUTS or defecatory dysfunction as their primary complaint. A growing body of literature indicates that increased pelvic floor tone underlies many urinary, gastrointestinal,

110 musculoskeletal injuries, such as sacroiliac joint dysfunction or hip osteoarthritis, all highly

7

111	prevalent conditions. Clinical identification of increased pelvic floor tone is subjective and
112	provider-dependent, relying on discriminate vulvar, vaginal, and rectal examination to identify
113	hypertonicity of the levator ani and obturator internus musculature. (6) (7)
114	
115	Beyond the diagnosis, there is little guidance on treatment pathways. While multiple clinical
116	trials and observational studies have sought to establish the efficacies of a range of treatments
117	for HTPFD, there is considerable variability in the level of peer-reviewed evidence. In addition,
118	head-to-head studies of therapeutic approaches are lacking, making it challenging for many
119	providers to determine an effective course of treatment, particularly when access to certain
120	therapeutic modalities, such as pelvic floor physical therapy (PFPT), can be limited. This lack of
121	guidance often leaves patients unable to access effective treatment or make informed decisions
122	surrounding their care.
123	
124	In the absence of guidelines or strong level I evidence, we sought to generate a treatment
125	algorithm based on using the Delphi method, a formal, systematic qualitative methodology, (8)
126	to compile expert opinion statements supported by the available literature pertinent to the
127	treatment of HTPFD. Compilation of these consensus statements into the first proposed
128	comprehensive treatment algorithm for women with HTPFD sought to facilitate clinician's
129	efforts to provide the best treatment options for these frequently debilitated patients.

8

131 METHODS

132 Design and Participants

133	The HTPFD treatment consensus was developed using a modified Delphi process. After
134	exemption from Institutional Review Board approval (UCLA IRB#21-001399), we identified a
135	range of practitioners with expertise in the diagnosis and management of HTPFD. Ten to 15
136	experts have been described as a minimum number for Delphi methodology to yield sufficient
137	results and ensure validity. (9) (10) Initial screening identified 32 practitioners who were either
138	academic clinicians with a track record of publications or academic speaking on HTPFD and/or
139	experts who had published online, book, and social media informational materials on HTPFD.
140	Twenty-five of these practitioners confirmed that HTPFD currently comprised at least 20% of
141	their patient population; 12 of these specialists agreed to participate, reflecting geographic
142	diversity and balanced representation of the multiple specialties.
143	
144	Prior to initiating the Delphi process, the intended scope of the practice algorithm was outlined,
145	and group members were asked to review a panel of literature containing pertinent clinical
146	trials and systematic reviews. The definition of HTPFD was provided to the participants as per
147	the International Continence Society. (11) Web-based software Qualtrics (Provo, UT) was used
148	to administer confidential surveys to participants.

149

150 Delphi Study

The Delphi method, an iterative process that uses a systematic progression of repeated rounds
of voting, is an effective process for determining expert group consensus where there is little

9

153	definitive evidence. (8) The process was conducted in three phases which took place between
154	September and December 2021 (Figure 1). To develop the initial statements, a literature review
155	was conducted to identify current evidence regarding options and efficacy of treatments for
156	HTPFD. Relevant information was collected from studies regarding best practices on how to
157	treat HTPFD, which were formulated by the study team into 31 statements for the Round 1
158	questionnaire. Survey questions used a 5-point Likert scale for participants to rate their level of
159	agreement with questions. (12) There was also opportunity for short comments explaining their
160	rationale for agreement or disagreement with statement. Consensus was defined as 70% or
161	more of the members voting in agreement. (13) (14) Statements with \geq 70% of agreement
162	(either strongly agree and agree; or strongly disagree and disagree) were interpreted as
163	"appropriate" or "inappropriate" to include in the guidelines, respectively. Statements that did
164	not meet consensus were revised and reposed to the group in the next round. New concepts
165	that were presented by at least three individual experts were incorporated into the next round
166	of statements.
167	
168	In phase two, the revised Round 2 questionnaire was sent to all participants and again
169	participants were asked to rate level of agreement on a 5-point Likert scale. Results from Round
170	2 were analyzed, and a treatment pathway was developed by the study team based on
171	consensus statements (Round 3). In phase three, the provisional treatment pathway was
172	presented to experts and qualitative and quantitative agreement was captured. Experts were
. = 0	

also asked additional qualitative questions about how they advise patients in resource limited

174 settings.

175

- 176 Statistical analysis
- 177 Aggregated data were stored and analyzed in Microsoft Excel for Mac (V16.16.16; Microsoft
- 178 Corporation, Redmond, WA).

11

180 **RESULTS**

181	A total of 4 American Board of Urology (ABU)-certified female pelvic medicine and
182	reconstructive surgery (FPMRS) urologists, 3 American Board of Obstetrics and Gynecology
183	(ABOG)-certified urogynecologists, 2 minimally invasive gynecologists, and 3 American Board of
184	Physical Therapy Specialties (ABPTS)-certified Women's Clinical Health Specialist physical
185	therapists participated in this effort. The treatment consensus was developed and confirmed in
186	an electronic, three-phase, modified Delphi process. A total of 31 statements were reviewed by
187	the HTPFD expert group members at the first Delphi round with 10 statements reaching
188	consensus. The 21 statements that did not reach consensus were reviewed and revised to
189	clarify ambiguities. Some statements were divided into two statements to aid in clarification. In
190	total, 28 statements were included in the second Delphi survey and 17 of these statements
191	reached consensus (Table 1). After the second round, it was determined that the statements
192	that had not reached consensus were because of absence of evidence rather than ambiguity in
193	wording (Appendix 1). A treatment pathway (Figure 2) was generated and evaluated by the
194	group members in the third Delphi survey, which met clinical consensus.
195	

Ultimately, the experts reached consensus that HTPFD treatment should be arranged into four
tiers based on available data and perceived effectiveness and invasiveness of the therapy.
Treatment approaches that did not reach expert consensus were not included in the final
treatment algorithm. Experts unanimously agreed that after the diagnosis of HTPFD is made,
patients should be referred to PFPT and counseled on home-based options for symptom
control. Behavioral interventions include timed voiding, urge suppression, and dietary

202	modifications for bowel and bladder symptoms. Home-based stretching exercises with the goal
203	of pelvic floor relaxation and yoga should be routinely recommended. At the time of diagnosis
204	an evaluation should rule out any extra-pelvic myofascial contributions, such as lower extremity
205	joint or spinal pathology, and if identified, a referral should be made to the appropriate
206	specialists for management in conjunction with the pelvic floor measures.
207	
208	Pelvic Floor Physical Therapy (PFPT)
209	There was unanimous consensus that PFPT should be offered as first-line treatment for HTPFD.
210	Consensus was met that PFPT should be employed for a least 8-12 weeks, noting that patients
211	with a longer symptom history may require a greater number of sessions to appreciate
212	improvement with PT. PFPT is aimed at pelvic floor relaxation, not strengthening, employing
213	techniques such as myofascial release and dry needling. Following the initial treatment, women
214	who improve with PFPT may continue therapy until the symptoms stabilize or resolve. Patients
215	may then be discharged with self-management techniques for symptom maintenance and for
216	the treatment of minor flares. After 4-6 months of stable symptoms, patients may follow up on
217	an as-needed basis. Experts agreed that the goal of PFPT is to facilitate initial improvements
218	and provide sufficient training to allow patients to manage symptoms and minor flares with
219	home-based treatment.
220	
221	Experts agreed that second-line therapies, such as tender point injection (TPI) and vaginal
222	suppositories, can be added to PFPT in patients whose progress has plateaued without
223	sufficient improvement or who are not initially able to tolerate therapy. Experts indicated

224	techniques such as biofeedback and dry needling may be employed at the discretion of the
225	physical therapist and do not need to be specifically requested by the clinician. If symptoms do
226	not improve with PFPT, then an alternative diagnosis should be considered before progression
227	to second-line options.
228	
229	Second Line Therapies
230	Vaginal Muscle Relaxants
231	Diazepam was the most prescribed vaginal suppository with the goal of muscle relaxation,
232	however other viable options include baclofen, cyclobenzaprine and tizanidine. Vaginal
233	administration was preferred by the experts over oral administration.
234	
235	Tender Point Injections (TPI)
236	A myofascial trigger point is a tender nodule within a taught band and is more recently being
237	referred to as tender point with increased tone. (15) Tender points often accompany HTPFD,
238	however not all hypertonic muscles have tender points and thus this therapy is most useful for
239	patients with identifiable tender points on exam. To identify an appropriate site for injection,
240	pelvic floor muscles are palpated perpendicular to its fiber orientation for a taut band. The taut
241	band is then palpated within its fiber direction for the most tender spot that reproduces or
242	refers pain. Injection of local anesthetic is targeted at this site. Consensus was reached that a
243	plain local anesthetic (e.g., 0.25%-0.5% bupivacaine) should be used. The majority of experts
244	did not recommend adding steroid to the injection mixture. This is helpful for patients who
245	cannot tolerate PFPT due to a high level of pain or who have plateaued with PFPT. The goal of

246	the TPIs is to downregulate the guarding reflex and allow for further relaxation of the muscle.
247	While response to TPI can be a good prognostic sign, if a patient does not respond to an initial
248	injection, repeated injections are not warranted. Experts did not advocate isolated pudendal
249	blocks in isolation were useful for treating HTPFD.
250	
251	Cognitive Behavioral Therapy (CBT)
252	CBT has been shown to make a clinically meaningful improvement in pain and psychosexual
253	function in patients with vestibulodynia and other chronic pain conditions thus experts
254	supported its use in HTPFD. (16) (17)
255	
256	Third-Line Therapy
257	OnabotulinumtoxinA (BTXA)
258	Experts reached consensus that injection with onabotulinumtoxinA is helpful for women with
259	refractory myofascial pelvic pain and should be the third-line option for women who have been
260	minimally responsive to other therapies. Experts reached consensus that BTXA injections should
261	be targeted at the myofascial sources of hypertonicity or pain, rather than administered in a
262	single template fashion, and that bilateral injection is preferred over unilateral. Repeat
263	injections is not recommended if there is no response to the first injection.
264	
265	Fourth-Line Therapy
266	Sacral Neuromodulation (SNM)

- 267 Experts anecdotally reported that SNM for urinary urgency and frequency in the setting of
- 268 HTPFD is sometimes effective to relieve pain, as well as LUTS. Given the paucity of data,
- 269 however, experts felt SNM should only be used in patients who have failed other therapies and
- should not be recommended in the absence of refractory frequency and urgency as SNM used
- 271 primarily for HTPFD would be an off-label use.
- 272
- 273

16

274 **DISCUSSION**

275	Here, we present a first-of-its-kind treatment algorithm for patients with HTPFD. While the first
276	line option of PFPT easily met consensus among our panel of national experts, later lines of
277	therapy with less evidence were supported based on expert opinion and anecdotal success.
278	Specifics regarding technique and dosing of second- and third-line therapies did not meet
279	consensus due to lack of high-quality evidence and heterogenicity in practice patterns. This
280	highlights areas where further research is needed to help refine this treatment algorithm and
281	improve the care of HTPFD.
282	
283	While PFPT has the most high-quality data to support its use, there are challenges with its
284	application. Most patients cannot identify an appropriate provider, experience long waits, or
285	undergo inadequate or inappropriate treatment. Inadequately trained therapists may focus on
286	muscle strengthening techniques, which exacerbates HTPFD. (18) Finding a skilled provider is
287	challenging as only 305 specialist therapists in the U.S. are registered on the American Physical
288	Therapy Association website; multiple states have only a few board-certified therapists. Uptake
289	and attendance with prescribed PFPT for HTPFD is poor, between 15-40%. (19) (20) Even when
290	delivered by well-trained personnel, PFPT is only effective for two-thirds of patients. (6) In
291	addition, patients need to be physically and cognitively intact and able to actively participate in
292	such therapies. Multiple barriers to starting and completing PFPT have also been identified, and
293	there are no accepted therapeutic equivalents for patients who cannot access physical therapy,
294	cannot participate in self-care, or fail to respond to this approach. (21)
295	

17

296	Despite limited guidance regarding formulation, dose, and administration, intravaginal
297	diazepam, a second-line treatment option in the algorithm, is increasingly being used off-label
298	for HTPFD management. (22) (23) Dosing has been adapted from oral dosing and experts felt a
299	starting dose of 5-10 mg vaginally was appropriate (Table 2) . Studies have shown that vaginally
300	administered diazepam results in lower peak serum plasma concentrations, longer half-life, and
301	fewer side effects, supporting the recommendation for vaginal over oral administration. (23)
302	(24) As there are no commercially available vaginal diazepam formulations, and compounded
303	medications are typically not covered by insurance, this treatment method can pose a financial
304	barrier for some patients. As the absorption of oral tablets placed vaginally is poor and
305	therapeutic benefit is reported to be less effective, it was not felt to be a universally acceptable
306	alternative. (25) Until insurance coverage improves for compounded vaginal preparations, this
307	therapy is not a universally accessible option.
308	
309	Psychosocial factors are well known to play a role in chronic pain, dictating severity and
310	prognosis. Comorbid depression and anxiety among women with chronic pelvic pain are
311	reported as high as 66%. (26) In addition, central sensitization, or the amplification of the
312	central nervous system response to peripheral input, may also occur in patients who experience
313	chronic pain. The combination of these factors highlights how CBT may be an acceptable

314 treatment option for pain due to HTPFD and pain-related depression and anxiety. Although

315 studies of CBT in patients with HTPFD are lacking, strong evidence for its benefits in a wide

316 range of chronic pain disorders and low risk of harm make CBT a reasonable second-line

317 therapy.

2	1	Q
J	-	10

319	While off-label pelvic floor BTXA injection has been used successfully for HTPFD, there is a wide
320	variation in its use and application. Clinically significant reduction in pain score and resting
321	muscle tone are observed across studies despite wide variability in dose, number of injection
322	sites, and method of injection. (27) Experts indicated injections should be bilateral and targeted
323	to hypertonic muscles using 10-40 units per muscle group. However, there remain many
324	unanswered questions regarding optimal injection technique, identification of injection sites
325	and injection amount that needs further investigation with larger randomized controlled trials
326	before definitive recommendations on BTXA can be put forth.
327	
328	There are no studies specifically evaluating the use of SNM for the treatment of HTPFD. SNM's
329	therapeutic effect in treating HTPFD is hypothesized to be related to reviving brainstem
330	autoregulation and reset the function of the pelvic floor as evidence by its utility in patients
331	with Fowler's syndrome. (28) Furthermore, SNM improves pain scores between 35 to 52% in
332	patients with non-IC/BPS chronic pelvic pain, including those with HTPFD. (29) While the expert
333	panel did not feel SNM should be used in patients without urinary or fecal urgency and
334	frequency, data suggest there may be a benefit of SNM for HTPFD alone even in the absence of
335	these complaints; further efforts are needed to evaluate this indication.
336	
337	Recognizing that the first- and second-line therapies listed in the algorithm are only accessible
338	in resource-rich settings, we specifically asked experts for options in resource-limited settings.
339	Virtual PFPT has increased accessibility in recent years, and experts felt this was an acceptable

340	alternative for patients with no or limited in-person options. The caveat to this is that it must be
341	clearly communicated that therapy should focus on pelvic floor relaxation. Experts also felt
342	progression straight to vaginal muscle relaxants and TPIs was a reasonable option. Overall,
343	experts reiterated their frustration that patients experience numerous barriers to obtaining
344	even these limited options, and improved insurance coverage and access to care is needed to
345	make these therapies more accessible. Sociodemographic inequalities have been highlighted as
346	barriers to pain management access and may be even greater in patients with HTPFD. (30)
347	
348	The strength of this novel consensus algorithm for the treatment of HTPFD derives from broad
349	experiences of an expert panel with diverse medical specialties and geographic locations,
350	strengthening the generalizability of this algorithm. However, this algorithm is limited in the
351	ability to provide specific guidance on the application of the therapeutics beyond PFPT due to
352	poor quality research. Even retrospective studies on an HTPFD population are limited by no
353	specific ICD10 diagnosis codes for HTPFD. Without wider recognition of this condition,
354	improvements in the diagnostic recognition and therapeutic offerings will continue to stagnate.
355	
356	With this expert-driven treatment algorithm, patients can now progress through treatment in a
357	systematic fashion. This will give providers more confidence when recommending therapies
358	and patients more confidence that additional options are available if they do not respond or
359	cannot access first-line options. This will also allow for further studies on responses to therapy,
360	improving the quality of data on these treatment decisions. In turn, this algorithm can be
361	revised and updated as research develops in this field.

20

362 Conclusion:

363	In summary, this algorithm was created by a diverse group of experts according to rigorous
364	criteria to generate a consensus treatment pathway for HTPFD supported by available
365	literature. PFPT is unanimously agreed upon to be first-line treatment of this condition. The
366	second-, third-, and fourth-line options are available for patients who do not adequately
367	respond to PFPT. In general, the expert panel reached consensus that research on the
368	treatment of HTPFD has been limited due by diagnostic challenges and poor awareness of this
369	condition. With clear treatment recommendations, providers can guide patients through
370	treatment of HTPFD in a more seamless manner, improving awareness, efficacy, outcomes and

371 satisfaction with care.

21

372 REFERENCES

373


374 Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218 2020 [135(3):e98-e09. 1. 375 doi:10.1097/AOG.00000000003716]. Available from: https://www.acog.org/clinical/clinical-376 guidance/practice-bulletin/articles/2020/03/chronic-pelvic-pain. 377 2. Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: 378 Prevalence, health-related quality of life, and economic correlates. Obstetrics and gynecology. 379 1996;87(3):321-7. 380 Ross V, Detterman C, Hallisey A. Myofascial Pelvic Pain: An Overlooked and Treatable 3. 381 Cause of Chronic Pelvic Pain. J Midwifery Womens Health. 2021;66(2):148-60. 382 Westbay LC, Adams W, Kistner M, Brincat C, Bresler L, Yang LC, et al. Clinical Outcomes 4. 383 of a Multidisciplinary Female Chronic Pelvic Pain Program. Female Pelvic Med Reconstr Surg. 384 2021;27(12):753-8. 385 Voorham-van der Zalm PJ, Lycklama ANGAB, Elzevier HW, Putter H, Pelger RCM. 5. 386 "Diagnostic investigation of the pelvic floor": a helpful tool in the approach in patients with 387 complaints of micturition, defecation, and/or sexual dysfunction. J Sex Med. 2008;5(4):864-71. 388 6. Bedaiwy MA, Patterson B, Mahajan S. Prevalence of myofascial chronic pelvic pain and 389 the effectiveness of pelvic floor physical therapy. J Reprod Med. 2013;58(11-12):504-10. 390 7. Faubion SS, Shuster LT, Bharucha AE. Recognition and management of nonrelaxing 391 pelvic floor dysfunction. Mayo Clin Proc. 2012;87(2):187-93. 392 Meshkat B CS, Gethin G, et. al. Using an e-Delphi technique in achieving consensus 8. 393 across disciplines for developing best practice in day surgery in Ireland. J Hosp Adm. 2014;3(4). 394 Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. 9. 395 Consensus development methods, and their use in clinical guideline development. Health 396 Technol Assess. 1998;2(3):i-iv, 1-88. 397 10. Giannarou L ZE. Using Delphi technique to build consensus in practice. Int J Bus Sci Appl 398 Manag. 2014;9(2):65-82. 399 Messelink B, Benson T, Berghmans B, Bo K, Corcos J, Fowler C, et al. Standardization of 11. 400 terminology of pelvic floor muscle function and dysfunction: report from the pelvic floor clinical 401 assessment group of the International Continence Society. Neurourol Urodyn. 2005;24(4):374-402 80. 403 12. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, et al. Systems for grading the 404 guality of evidence and the strength of recommendations I: critical appraisal of existing 405 approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38. 406 13. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J 407 Adv Nurs. 2000;32(4):1008-15. 408 14. T S. The Delphi Technique: An Adaptive Research Tool. Br J Occup Ther. 1998;61(4):153-409 6. 410 15. Frawley H, Shelly B, Morin M, Bernard S, Bo K, Digesu GA, et al. An International 411 Continence Society (ICS) report on the terminology for pelvic floor muscle assessment. 412 Neurourol Urodyn. 2021;40(5):1217-60.

22

413 16. Goldfinger C, Pukall CF, Thibault-Gagnon S, McLean L, Chamberlain S. Effectiveness of 414 Cognitive-Behavioral Therapy and Physical Therapy for Provoked Vestibulodynia: A Randomized 415 Pilot Study. J Sex Med. 2016;13(1):88-94. 416 Urits I, Callan J, Moore WC, Fuller MC, Renschler JS, Fisher P, et al. Cognitive behavioral 17. 417 therapy for the treatment of chronic pelvic pain. Best Pract Res Clin Anaesthesiol. 418 2020;34(3):409-26. 419 Hoffman D. Central and peripheral pain generators in women with chronic pelvic pain: 18. 420 patient centered assessment and treatment. Curr Rheumatol Rev. 2015;11(2):146-66. 421 19. Woodburn KL, Tran MC, Casas-Puig V, Ninivaggio CS, Ferrando CA. Compliance With 422 Pelvic Floor Physical Therapy in Patients Diagnosed With High-Tone Pelvic Floor Disorders. 423 Female Pelvic Med Reconstr Surg. 2021;27(2):94-7. 424 20. Shannon MB, Genereux M, Brincat C, Adams W, Brubaker L, Mueller ER, et al. 425 Attendance at Prescribed Pelvic Floor Physical Therapy in a Diverse, Urban Urogynecology 426 Population. Pm&R. 2018;10(6):601-6. 427 21. Zoorob D, Higgins M, Swan K, Cummings J, Dominguez S, Carey E. Barriers to Pelvic Floor 428 Physical Therapy Regarding Treatment of High-Tone Pelvic Floor Dysfunction. Female Pelvic 429 Med Re. 2017;23(6):444-8. 430 22. Crisp CC, Vaccaro CM, Estanol MV, Oakley SH, Kleeman SD, Fellner AN, et al. Intra-431 vaginal diazepam for high-tone pelvic floor dysfunction: a randomized placebo-controlled trial. 432 Int Urogynecol J. 2013;24(11):1915-23. 433 23. Stone RH, Abousaud M, Abousaud A, Kobak W. A Systematic Review of Intravaginal 434 Diazepam for the Treatment of Pelvic Floor Hypertonic Disorder. J Clin Pharmacol. 2020;60 435 Suppl 2:S110-S20. 436 Larish AM, Dickson RR, Kudgus RA, McGovern RM, Reid JM, Hooten WM, et al. Vaginal 24. 437 Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. J Sex Med. 438 2019;16(6):763-6. 439 25. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release. 440 2005;103(2):301-13. 441 26. Siqueira-Campos VME, Da Luz RA, de Deus JM, Martinez EZ, Conde DM. Anxiety and 442 depression in women with and without chronic pelvic pain: prevalence and associated factors. J 443 Pain Res. 2019;12:1223-33. 444 27. Meister MR, Brubaker A, Sutcliffe S, Lowder JL. Effectiveness of Botulinum Toxin for 445 Treatment of Symptomatic Pelvic Floor Myofascial Pain in Women: A Systematic Review and 446 Meta-analysis. Female Pelvic Med Reconstr Surg. 2021;27(1):e152-e60. 447 28. Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral 448 neuromodulation for urinary retention. J Urol. 2005;174(6):2268-72. 449 29. Mahran A, Baaklini G, Hassani D, Abolella HA, Safwat AS, Neudecker M, et al. Sacral 450 neuromodulation treating chronic pelvic pain: a meta-analysis and systematic review of the 451 literature. Int Urogynecol J. 2019;30(7):1023-35. 452 Knoebel RW, Starck JV, Miller P. Treatment Disparities Among the Black Population and 30. 453 Their Influence on the Equitable Management of Chronic Pain. Health Equity. 2021;5(1):596-454 605. 455 456

462 Figure 1 – Diagrammatic Overview of Modified Delphi Process. Multiple questionnaire rounds

- 463 were sent to the panel of experts to work toward a consensus opinion. The participants were
- 464 allowed additional free-text responses to help generate revised statements in subsequent
- 465 rounds. In later rounds, information brought forth by other experts was also included to help
- 466 refine consensus statements. After the third round, a final treatment algorithm was generated
- 467 from the consensus statements and approved by all members.
- 468




469

Figure 1: Diagrammatic overview of modified Delphi process

470 Figure 2 – Treatment Algorithm for High Tone Pelvic Floor Dysfunction. The consensus

- 471 statement regarding treatment approaches for HTPFD were organized into an algorithm with
- 472 levels of treatment ranging from least invasive and most evidence-based to more invasive
- 473 approaches with weaker supporting evidence.
- 474

Treatment Algorithm for High Tone Pelvic Floor Dysfunction



478 Table 1 – Statements That Met Consensus

Statement	No. (%) Agreement (n=11)
Pelvic Floor Physical Therapy	
Pelvic floor physical therapy should be tried for 8-12 weeks before reassessment. Optimal treatment schedule would be 1-2 sessions per	11 (100)
week for at least 8 weeks, ideally 12 weeks.	
Women with improvement and stabilization on PFPT should be discharged with a home exercise program to maintain improvement.	11 (100)
Women with improvement and stabilization on PFPT should be discharged with a home exercise program and follow up with MD or APP after 4-6 months to check for sustained response	8 (73)
There was a mixed response on the role of biofeedback. Some believe it is considered a standard part of pelvic floor physical therapy and some feel it should be requested specifically by the clinician. There are promising studies to support biofeedback's utility in HTPFD. The literature presents evidence for the efficacy and effectiveness of pelvic floor muscle training performed together with adjunctive therapies (biofeedback, vaginal cones, electrical stimulation) as being greater than pelvic floor exercises performed alone (or using behavioral therapy alone). Pelvic floor muscle surface electromyographic biofeedback does NOT need to be specifically requested by the clinician for patients with HTPFD.	10 (91)
Pelvic floor muscle surface electromyographic biofeedback should be performed at the discretion of the physical therapist and does not need to be called out specifically in the HPTFD treatment algorithm.	11 (100)
OnabotulinumtoxinA	1
Injection of onabotulinumtoxinA into hypertonic pelvic floor muscles should be used in conjunction to PFPT in women who do not achieve adequate improvement with PT alone.	8 (73)
When using onabotulinumtoxinA in the pelvic floor, should a standard template injection or a targeted injection at hypertonic muscles be used? Targeted	9 (82)
Should injections of onabotulinumtoxinA be performed unilateral or bilateral? Bilateral	8 (73)
If no improvement with onabotulinumtoxinA after how many sessions do you move on to another therapy? 1-2	10 (91)

There was a wide variation in the amount of botuliumtoxin per muscle	8 (73)
group used from 10 to 50 units per muscle group. Units per muscle	
group depends on how many muscle groups are being targeted but is	
somewhere between 10-40 units per muscle group not to exceed 360	
units in 3 months.	
Vaginal Muscle Relaxants	
Vaginal administration of benzodiazepines, such as diazepam, may	8 (73)
reduce pelvic floor muscle tone. Although individual response is	
variable, it is worth a trial given low risk and invasiveness of therapy.	
Studies have shown that vaginally administered diazepam results in	8 (73)
lower peak serum plasma concentrations, and longer half-life, resulting	
in fewer side effects. Thus, vaginal administration is preferred over oral	
administration.	
Which of the following vaginal muscle relaxants do you use? Diazepam	8 (73)
Cognitive Behavioral Therapy	
80% of respondents believed that psychological counseling or CBT	8 (73)
should be offered at some point in the treatment algorithm. Do you feel	
patients should be offered CBT or psychological counseling as part of the	
initial assessment after diagnosis of HTPFD is made, OR should it be a	
second line option if no improvement is made with PFPT. Second line	
Tender Point Injections (TPI)	
There was a mixed response on the use of pudendal blocks in HTPFD.	8 (73)
Respondents felt that pudendal blocks should only be used if there are	
signs of pudendal neuralgia or as a diagnostic tool to see if the process is	
peripheral or sympathetically maintained. Others felt this is to treat a	
different pathophysiology that HTPFD. Pudendal blocks do not have role	
in pure high-tone pelvic floor dysfunction.	
Sacral Neuromodulation	
There was a mixed response to the use of sacral neuromodulation	9 (82)
(SNM) for HTPFD. 60% of respondents believed it should be included in	
the treatment algorithm in some capacity however due to the	
invasiveness of the procedure it should be reserved as a "last resort"	
option, after trial of less invasive options. Studies have shown the utility	
of SNM in patients with chronic pelvic or bladder pain with	
improvement in pelvic pain and urgency with 80% satisfaction	
(Marinkovic, 2011). The goal of SNM is to target LUT symptoms as well	
as pelvic pain. Do you agree with the use of SNM as a 4th line option for	
HTPFD after other options have been tried?	

Therapies Not to Include	
Home therapies such as stretching, heating pads and yoga should be	9 (82)
used as first line therapy for HTPFD.	disagreement
At home TENS units can be considered as an alternative to PFPT for	10 (91)
treatment of HTPFD.	disagreement
Order of therapy	
Pelvic floor physical therapy should be first line therapy for high-tone	11 (100)
pelvic floor dysfunction.	
Vaginal muscle relaxants, TPI, and BTX-A should all be considered	8 (73)
second line therapies.	
Second line treatment options for HTPFD should include (choose 3)	8 (73)
Vaginal muscle relaxants, TPIs	
Third line treatment options for HTPFD should include (choose 3) BTX-A	8 (73)
Fourth line treatment options for HTPFD should include (choose 3)	8 (73)
Sacral neuromodulation	
Based on consensus opinions determined from Questionnaire 1, the	9 (82)
treatment algorithm should include PFPT as first line option.	

Medication	Dosing Options
Diazepam	5-10 mg as needed up to three times per day ²⁴
Tizanidine	2 to 4 mg at bedtime*
Baclofen	30mg daily to three times a day*
Cyclobenzaprine	5 to 10mg at bedtime*

481 Table 2 – Vaginal Muscle Relaxant Options

482 *Based on expert opinion

31


483 Appendix 1- Statements That Did Not Meet Consensus

Statement	No. (%)
	Agreement (n=11)
Biofeedback	(11-11)
Women who continue to have moderate to severe symptoms (i.e.	4 (36)
interfering with daily activities or sleep) after completion of pelvic floor	
physical therapy should be treated with biofeedback.	
Biofeedback should be first line for the treatment of HTPFD.	3 (27)
Biofeedback should be used if PFPT has been tried and success as plateaued or not been achieved.	6 (55)
There is a standard protocol that is used for biofeedback?	2 (18)
If pelvic floor EMG biofeedback is available in the clinician's office (i.e. urostym) it can be considered as an alternative to PFPT particularly for patients who cannot access PFPT.	3 (27)
Vaginal Muscle Relaxants	
For patients who cannot afford compounded vaginal muscle relaxants, oral muscle relaxants are the best alternative.	2 (18)
For patients who cannot afford compounded vaginal muscle relaxants, oral muscle relaxants placed vaginally are the best alternative.	3 (27)
Vaginal muscle relaxants should be tried before pelvic floor TPI or BTX-A is considered.	4 (36)
Vaginal muscle relaxants should be used in conjunction with PFPT for the treatment of HPTFD.	4 (36)
BTX-A and TPI	
BTX-A ideally should be combined with a local anesthetic like Marcaine. The anesthetic portion can be helpful if the HTPFM is due to a sensory pain trigger at the periphery that can be blocked. Thus, the person can learn to relax the muscle once the trigger is removed.	6 (55)
Ideal timing of TPI is injection in the physician's office followed by an immediate PT session within 1 hour.	3 (27)
60% of respondents agreed that BTX-A should be considered in conjunction with PFPT if there is a plateau in improvement. In this situation BTX-A should be considered based on the recommendation by PFPT.	7 (64)
BTX-A or TPI are more effective than vaginal muscle relaxants and thus should be tried first.	3 (27)

2	2
-	/
ັ	~

Injection of local anesthetic to hypertonic muscles should be used in	7 (64)
conjunction with BTX-A.	
Injection of local anesthetic to hypertonic muscles helps treat HTPFD.	6 (55)
How many units of BTX-A should be used per muscle group?	No
	consensus
Pudendal blocks should be used in conjunction with BTX-A injections to the	0 (0)
pelvic floor.	
To determine a patient's response to BTX-A injections, an initial trial in the	3 (27)
office of an injection into the hypertonic muscle should be used. If there is	
improvement, then BTX-A should be used for subsequent injections. If no	
improvement alternative therapies should be recommended.	
Injection of BTX-A into hypertonic pelvic floor muscles should only be used	6 (55)
in patients who are refractory to biofeedback, PFPT and vaginal muscle	
relaxants.	
Sacral Neuromodulation	1
Sacral neuromodulation should be considered if patient has failed home	5 (45)
therapy, biofeedback, pelvic floor physical therapy, vaginal muscle relaxants	
and TPIs.	
Sacral neuromodulation should be considered if patients have failed PFPT.	4 (36)
Alternative Therapies	
Women with minimal or no improvement with PFPT should be reassessed	5 (45)
and referred for evaluation with a psychiatrist or orthopedist to assess for	
extra-pelvic sources of pain.	
There is evidence to support the use of home therapies such as stretching,	5 (45)
heating pads and yoga for the treatment of HTPFD.	
At home TENS units have a role in the treatment of HTPFD.	2 (18)

Treatment Algorithm for High Tone Pelvic Floor Dysfunction






Figure 1: Diagrammatic overview of modified Delphi process